RP-59500, A NEW STREPTOGRAMIN HIGHLY-ACTIVE AGAINST RECENT ISOLATES OF NORTH-AMERICAN STAPHYLOCOCCI

被引：29

作者：

ARCHER, GL

AUGER, P

DOERN, GV

FERRARO, MJ

FUCHS, PC

JORGENSEN, JH

LOW, DE

MURRAY, PR

RELLER, LB

STRATTON, CW

WENNERSTEN, CB

MOELLERING, RC

机构：

[1] NEW ENGLAND DEACONESS HOSP, DEPT MED, BOSTON, MA 02215 USA

[2] DUKE UNIV, MED CTR, DURHAM, NC 27710 USA

[3] VANDERBILT UNIV, MED CTR, NASHVILLE, TN 37240 USA

[4] BARNES HOSP, ST LOUIS, MO 63110 USA

[5] INST CARDIOL MONTREAL, MONTREAL H1T 1C8, QUEBEC, CANADA

[6] MED CTR HOSP, SAN ANTONIO, TX USA

[7] MT SINAI HOSP, TORONTO M5G 1X5, ONTARIO, CANADA

[8] VIRGINIA COMMONWEALTH UNIV, MED COLL VIRGINIA, RICHMOND, VA 23298 USA

[9] UNIV MASSACHUSETTS, MED CTR, WORCESTER, MA 01605 USA

[10] MASSACHUSETTS GEN HOSP, BOSTON, MA 02114 USA

[11] ST VINCENTS HOSP & MED CTR, PORTLAND, OR USA

来源：

DIAGNOSTIC MICROBIOLOGY AND INFECTIOUS DISEASE | 1993年 / 16卷 / 03期

关键词：

D O I：

10.1016/0732-8893(93)90113-L

中图分类号：

R51 [传染病];

学科分类号：

100401 ;

摘要：

To assess the potential clinical utility of RP 59500, 10 investigators from separate locations in the United States and Canada each tested approximately 200 current isolates of staphylococci (Staphylococcus aureus and coagulase-negative staphylococci) by a standard protocol. RP 59500 was highly active (MIC90 less-than-or-equal-to 2 mug/ml) against all strains, including those that were resistant to oxacillin, ciprofloxacin, erythromycin, and spiramycin.

引用

页码：223 / 226

页数：4

共 8 条

[1] INVITRO ANTISTAPHYLOCOCCAL ACTIVITY AND TESTING OF RP-59500, A NEW STREPTOGRAMIN, BY 2 METHODS [J].